Please review, observe and realize that the opinions expressed by these individuals are based upon wisdom guided by experience. It is not our intention to suggest or state that anyone deciding to get the vaccine, or has already received one or both doses of the vaccine is headed for adverse or ill effects sometime into the future.
We simply do not know. What we are wanting to emphasize is simply, EUA vaccines should be reserved for viruses that hold a significant risk for morbidity or mortality, such as ebola, smallpox, polio, etc.
Viral Vector Vaccines are a new type of vaccine, that is designed from the ground up to have messenger RNA or mRNA (genetic material foreign to human DNA) to be delivered by a live virus or a synthetic material to act as a temporary “capsule” to allow the mRNA to enter into cells after being injected into your arm. Note that if the mRNA leaks from these synthetic capsules after injection, severe anaphylactic reactions that can result in death can occur.
Ebola Outbreak in Africa
With the evidence we have been able to collect and analyze to date, this is not been shown to be a virus that would otherwise warrant such risks in a treatment modality that has never been tested for safety and effectiveness. We simply do not know if this vaccine will be safe and effective, and how long it will remain safe and effective.
With this understanding, continue:
Before you chose to receive the unapproved experimental viral vector vaccine for the Wuhan Virus:
“The requisite FDA Phase 4 studies that the government requires for a FDA to approve a vaccine prior to administering a vaccine to a population to prove that it is safe and effective vaccine, is actually you, if you chose to get the experimental un-approved Moderna Vaccine.”
The Phase 4 studies for this experimental vaccine have NOT been done.
Usual Stages of Drug or Vaccine Development
You are the Phase 4 Study Group
The FDA and Moderna both state, that they do not know whether this vaccine is safe and effective, and that the phase 4 study that is ordinarily be required prior to the general public get the vaccine has not been done.
This vaccine has been released for emergency use only [EUA- emergency use authorization]. Note that emergency use authorization is done to release a vaccine to prevent significant death and morbidity from a disease that have a extremely high rate of disease and death, such as ebola, smallpox, or polio. These viruses have significant mortality rates that can be as high as 50-80% or greater.
The experimental Moderna Vaccine is being administered for a disease, Covid19, that has a mortality rate less that 0.045% and virtually 0% in anyone under 65 years of age with appropriate and timely treatment when necessary. This is really identical for the annual flu illnesses we see every year.
And according to both the FDA and Moderna, we do not know if this experimental vaccine is safe and effective against the Wuhan Virus.
Companies paying their employees to get the Vaccine when vaccine administration is low.
In our Nations Capitol, we have observed some Vaccine Clinics having to bribe people with free marijuana in order to get them to come in and get vaccinated. This is unbelievably unethical, and preposterous.
Oxford-AstraZeneca COVID-19 Vaccine code-named AZD1222, using as a vector the modified chimpanzee adenovirus ChAdOx1.
Note: there is to date No collected evidence to support that the human trials (the vaccines administered by the above mentioned companies) are dangerous; and there is no scientific evidence to suggest this from what we have observed to date. This can only be determined with extensive research and observations from stage 4 analysis, which is what is what the people throughout the world are when they receive these viral vector vaccines. The stage 4 analysis which is usually limited to volunteers typically over a span of years, is done prior to FDA approval and final release of a new vaccine. These viral vector vaccines presently being administered to the USA and the world are unapproved and considered experimental.
It is worth noting that, Merck Discontinued Development of their SARS-CoV-2/COVID-19 Vaccine Candidates because they learned that the vaccines immune responses were inferior to those seen following natural infection.
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.
Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio. Both of these are anti-viral medications, that will be essential in preventing disease morbidity and mortality in those patients who contact the virus and are unable themselves to prevent the virus from resulting in an increased viral load leading to significant cell invasion and cell death. Note, that for the most of us, our immune systems will be able to combat the illnesses caused by the present strain of the SARS coronavirus, as it has been observed that this virus has a 99.95% survival rate even without treatment.
Merck is instead going to center around treatments for those few individuals who are likely to benefit from medications to treat the illness in those few patients who actually become symptomatic and required treatment, such as mentioned in the MATH+ protocol.
Much cheaper and already for use, however, is Plaquenil or the generic brand hydroxychloroquine which has been shown to be effective against the SARS coronavirus as published studies revealed back in 2005.
